Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.53 |
| ▸ | UMPS | P11172 | 3/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.48 |
| ▸ | EIF4E | P06730 | 2/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17809088 | 1.00 | DNPH1 (0.53) | DNPH1UMPSP2RY6EIF4EFBP1 | |
| SCHEMBL18118158 | 1.00 | DNPH1 (0.53) | DNPH1UMPSP2RY6EIF4EFBP1 | |
| SCHEMBL15836223 | 1.00 | DNPH1 (0.53) | DNPH1UMPSP2RY6EIF4EFBP1 | |
| SCHEMBL17789097 | 1.00 | DNPH1 (0.53) | DNPH1UMPSP2RY6EIF4EFBP1 | |
| SCHEMBL14929195 | 1.00 | DNPH1 (0.53) | DNPH1UMPSP2RY6EIF4EFBP1 | |
| SCHEMBL14946152 | 1.00 | DNPH1 (0.53) | DNPH1UMPSP2RY6EIF4EFBP1 | |
| SCHEMBL26115033 | 0.91 | P2RY6 (0.52) | P2RY6 | |
| SCHEMBL14929352 | 0.90 | DNPH1 (0.43) | DNPH1UMPSP2RY6EIF4E | |
| SCHEMBL18574182 | 0.90 | DNPH1 (0.43) | DNPH1UMPSP2RY6EIF4E | |
| SCHEMBL14946382 | 0.90 | DNPH1 (0.43) | DNPH1UMPSP2RY6EIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4108671-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3590949-B1 | RIBONUCLEIC ACIDS CONTAINING N1-METHYL-PSEUDOURACILS AND USES THEREOF | MODERNATX INC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3590949-A1 | RIBONUCLEIC ACIDS CONTAINING N1-METHYL-PSEUDOURACILS AND USES THEREOF | ModernaTX, Inc. (US) | 2020-01-08 | — | — | EP | disclosed |
| US-20190160185-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2019-05-30 | — | — | US | disclosed |
| EP-2622064-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20170239374-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-24 | — | — | US | disclosed |
| US-9657295-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNATX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160264975-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2016-09-15 | — | — | US | disclosed |
| US-9334328-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160022774-A1 | DIAGNOSIS AND TREATMENT OF FIBROSIS | MODERNATX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20140371302-A1 | MODIFIED MRNAS ENCODING CELL-PENETRATING POLYPEPTIDES | MODERNATX, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014158795-A1 | DIAGNOSIS AND TREATMENT OF FIBROSIS | MODERNA THERAPEUTICS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013101690-A1 | MODIFIED MRNAS ENCODING CELL-PENETRATING POLYPEPTIDES | modeRNA Therapeutics (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2012045075-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | SCHRUM JASON (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022774-A1 | DIAGNOSIS AND TREATMENT OF FIBROSIS | MMP1, COL2A1, COL1A1 | DNPH1 4562/4885UMPS 1925/4885P2RY6 2970/4885 |
| US-20170239374-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, RNMT | DNPH1 402/4885UMPS 35/4885P2RY6 388/4885 |
| US-20190160185-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, RNMT | DNPH1 402/4885UMPS 35/4885P2RY6 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.